On March 17, the 2026 Yabuli Entrepreneurs Forum was held in Yabuli, Heilongjiang. With the theme Confidence, Opportunity, and a New Chapter, the forum brought together entrepreneurs from all sectors to discuss new paths for development. Eric Tse, Chief Executive Officer of Sino Biopharm (1177.HK) and Chairman of CTTQ Pharma and Beijing Tide Pharmaceutical, was invited to attend the opening ceremony and delivered a speech titled Growth Beyond Boundaries: The Path of Innovation and Establishment for Chinese Pharmaceutical Companies Amid Global Changes. 

In his speech, Eric Tse pointed out that the biopharmaceutical industry is facing a critical window for breaking through and establishing the new. This year's government work report from the Two Sessions listed biopharmaceuticals as an emerging pillar industry. At the same time, the iterative upgrading of AI technology and the rapid development of next-generation therapies such as Antibody-Drug Conjugates (ADCs), bispecific antibodies, and small nucleic acids are injecting strong momentum into the industry's development. Amid complex global economic shifts, Chinese pharmaceutical companies can only drive innovation, navigate economic cycles, and shape the future by proactively breaking the boundaries of perception, technology, and cooperation. 

In 2025, the number of innovative drugs approved for marketing in China reached 76, making it the world's second-largest country for first-time marketing of new molecular entities. Both the scale and number of out-licensing deals for innovative drugs hit record highs. However, a leap in scale does not equate to a corresponding say. Eric Tse pointed out that although domestic pharmaceutical companies benefit from a Demographic Dividend of Engineers, enabling rapid target discovery and development, they often struggle to advance international Phase III clinical trials due to high costs, frequently leading to difficulties in their overseas expansion. Therefore, industry breakthroughs require consolidating market forces. While accumulating capital through new models like overseas licensing, it is crucial to genuinely enhance basic research and original innovation capabilities to create more blockbuster products at the First-in-Class (FIC)/Best-in-Class (BIC) level. 

Currently, AI, as a New Quality Productive Force reshaping the entire drug R&D chain, is becoming a key lever for Chinese pharmaceutical companies to break through technological boundaries. As one of China's largest prescription drug companies, Sino Biopharm is comprehensively advancing intelligentization across R&D, production, marketing, and functional departments. Meanwhile, Sino Biopharm is collaborating deeply with leading companies like Huawei and ByteDance, leveraging its unique drug development and clinical data to incubate next-generation breakthrough therapies. It has also co-established the Beijing Key Laboratory of Smart Drug R&D with Peking University to create a closed-loop system from AI drug R&D to translation. 

Eric Tse noted that although Chinese pharmaceutical companies are making continuous breakthroughs in cutting-edge therapies, simple product exports or licensing deals are not enough to build lasting competitiveness. We need to evolve into Co-builders of the Global Value Network to break through scale bottlenecks and create world-class pharmaceutical companies.To this end, Sino Biopharm is driven by a dual-wheel approach of precise investment and M&A, along with extensive internal and external collaborations. The acquisitions of LaNova Medicines and Hygieia have initiated a new model of synergistic development between leading pharmaceutical companies and emerging forces. Strategic collaborations with multinational giants like Boehringer Ingelheim and Sanofi have set a benchmark for two-way empowerment in both domestic and overseas markets. In addition, Sino Biopharm plans to take the lead in establishing an international development alliance for biopharmaceutical companies in Shanghai, building a Multi-center Clinical Mutual Recognition System for the Asia-Pacific region and Belt and Road countries. This will help more Chinese innovative drugs to be launched quickly in the Belt and Road market and cover the global market faster. 

2026 marks the beginning of the 15th Five-Year Plan. Upgraded to an Emerging Pillar Industry, biopharmaceuticals will bear the important responsibility of driving economic growth. Eric Tse stated that Sino Biopharm will continue to strive towards its goal of becoming a world-class pharmaceutical company with a global market presence. He also called on entrepreneurs from all sectors to join forces and inject more confidence and opportunities into China's high-quality economic development. 

Disclaimer:
The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.